Smith & Nephew plc (LON:SN - Get Free Report) shares passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 1,026.32 ($13.83) and traded as high as GBX 1,080 ($14.55). Smith & Nephew shares last traded at GBX 1,061 ($14.29), with a volume of 1,689,118 shares changing hands.
Smith & Nephew Trading Down 0.7%
The company has a market cap of £11.67 billion, a PE ratio of 38.33, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62. The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The business has a 50-day simple moving average of GBX 1,039.13 and a 200-day simple moving average of GBX 1,028.87.
Insider Transactions at Smith & Nephew
In related news, insider Sybella Stanley acquired 3,810 shares of the business's stock in a transaction dated Wednesday, March 26th. The shares were acquired at an average price of GBX 1,101 ($14.83) per share, with a total value of £41,948.10 ($56,510.98). Also, insider Jeremy (Jez) Maiden bought 1,855 shares of the company's stock in a transaction that occurred on Thursday, May 1st. The stock was acquired at an average cost of GBX 1,070 ($14.41) per share, for a total transaction of £19,848.50 ($26,739.19). Corporate insiders own 0.19% of the company's stock.
About Smith & Nephew
(
Get Free Report)
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Read More
Before you consider Smith & Nephew, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Smith & Nephew wasn't on the list.
While Smith & Nephew currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
